X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds for the development of MLS-101 (lorundrostat) for the treatment of uncontrolled and resistant hypertension.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TCGX
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 08, 2024
Details:
MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. It is being evaluated in phase 3 clinical trials for the treatment of uncontrolled and resistant hypertension.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension and chronic kidney disease.
Lead Product(s): Lorundrostat
Therapeutic Area: Nephrology Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
The net proceeds from the public offering is used to fund the research and development of MLS-101 (lorundrostat). MLS-101 is a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of hypertension.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $220.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2023
Details:
The net proceeds from the public offering is used to fund the research and development of MLS-101 (lorundrostat). MLS-101 is a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of hypertension.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $192.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2023
Details:
The proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of MLS-101 (lorundrostat), and the remainder for working capital and general corporate purposes.
Lead Product(s): Lorundrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2023
Details:
MLS-101, a highly selective investigational aldosterone synthase inhibitor, met its primary endpoint with significant and clinically meaningful reduction in SBP in inadequately controlled hypertensive patients on at least two background antihypertensive medications.
Lead Product(s): MLS-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MLS-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
